-
-
Overview
-
MG 132 is a modified tripeptide that acts as proteasomal inhibitor. In 2006, MG 132 has been experimentally tested in in vitro cell-based and in vivo models for to assess its use in the medical treatment of Parkinsons disease.
Please contact us at for specific academic pricing.
-
- Properties
-
Overview